Treating Depression at Home: The FL-100 Headset Stimulates the Brain Without Medication
![]() |
| A depression treatment device from Flow Neuroscience |
Based on transcranial direct current stimulation (tDCS) technology
Flow Neuroscience, a Swedish neurotechnology company, has launched the FL-100 headset in the United States. It offers a home-based treatment option for adults suffering from moderate to severe major depressive disorder.
The device's launch follows its receipt of pre-market approval from the U.S. Food and Drug Administration (FDA) under the PMA P230024 pathway. It is a prescription device that provides electrical brain stimulation therapy while allowing for remote patient monitoring by the treating physician. According to a report by *Android Headlines*, the headset offers a non-pharmacological option that can be used either alone or alongside existing antidepressants, provided the patient does not have treatment-resistant depression.
How does the device work?
The wireless FL-100 headset utilizes transcranial direct current stimulation (tDCS) technology, which employs a low-intensity electric current to stimulate a specific area of the brain.
The device connects to a smartphone app and delivers an electric current—ranging from 0.5 to 2.0 milliamperes—to the left dorsolateral prefrontal cortex, a region associated with mood regulation and the control of cognitive functions. Although the treatment mechanism is relatively simple to use, it follows a specific treatment schedule.
Patients undergo 15 sessions—each lasting 30 minutes—over the first three weeks, followed by a transition to three sessions per week for maintenance therapy. A companion app manages the timing of stimulation sessions to prevent overuse and tracks symptom progression using validated clinical scales. The app also automatically synchronizes data on patient adherence with the prescribing physician, enabling remote monitoring of the patient's condition and treatment progress.
![]() |
| Depression Treatment Device |
Encouraging Clinical Results
The FL-100 technology is backed by clinical evidence, including findings from the 10-week, double-blind EMPOWER trial published in *Nature Medicine*. The study demonstrated that 57% of patients receiving active stimulation achieved full clinical remission, while approximately 63% of participants experienced a reduction in depression symptoms of at least 50%. Reported side effects were largely mild and transient, primarily consisting of slight skin redness and a mild tingling sensation at the contact points where the electrodes touched the forehead.
Over 65,000 Users
Flow Neuroscience is not starting from scratch in the US market; the company reports that its technology has already been used by more than 65,000 people across Europe, the UK, and Australia, supported by over 1,200 prescribing healthcare professionals.
With the launch of the FL-100 in the United States, the company is making the device available for prescription by psychiatrists, primary care physicians, and specialized medical practitioners. The company also offers the option of remote medical assessments for patients through the Flow Care telehealth network.
**Estimated cost: $500–$800**
Insurance coverage in the US for this type of treatment is still evolving; consequently, the out-of-pocket cost for the device and treatment is expected to range between $500 and $800. The launch of the FL-100 marks a significant milestone in the US home-based neuromodulation market, paving the way for the use of medically regulated brain stimulation devices outside of clinics and treatment centers, while maintaining remote physician monitoring of patients.


Leave a Comment